Set up of a protocol for heparin use in special patients
Low-molecular weight (LMW) heparins bring a series of advantages as compared to non-fractionated heparin (NFH), such as safety, efficacy, bioavailability, fewer monitoring, and persistent anti-coagulant response. There exist, however, a concern about their use in particular patients that may require...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-03-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/1081.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850180723809452032 |
|---|---|
| author | N. Manresa Ramón Mª D. Nájera Pérez Mª Ángeles Page del Pozo I. Sánchez Martínez Mª del M. Sánchez Catalicio V. Roldán Schilling |
| author_facet | N. Manresa Ramón Mª D. Nájera Pérez Mª Ángeles Page del Pozo I. Sánchez Martínez Mª del M. Sánchez Catalicio V. Roldán Schilling |
| author_sort | N. Manresa Ramón |
| collection | DOAJ |
| description | Low-molecular weight (LMW) heparins bring a series of advantages as compared to non-fractionated heparin (NFH), such as safety, efficacy, bioavailability, fewer monitoring, and persistent anti-coagulant response. There exist, however, a concern about their use in particular patients that may require a special control, such as those with renal failure, age over 75 years, obesity, and pregnancy. The aim of this study was the set up between the department of Pharmacy, Hematology, and Internal Medicine of a consensus protocol for the follow-up ad monitoring of LMWH in patients requiring a special control. For this purpose, we carried out a bibliographical review of the different heparins used under de above mentioned conditions. Based on the evidence available and the consensus among the members of the working group, we established a protocol that contained recommendations on prophylaxis, management and monitoring by means of the determination of anti-Xa factor. Besides, we included some clues on the therapeutic figures of anti-Xa and administration schedules for obtaining anti-Xa values within the range. Enoxaparin was the selected heparin given the evidence and its availability at our center. |
| format | Article |
| id | doaj-art-51e76b80d7764dce870a8d5e952fa144 |
| institution | OA Journals |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2014-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-51e76b80d7764dce870a8d5e952fa1442025-08-20T02:18:04ZengElsevierFarmacia Hospitalaria1130-63432171-86952014-03-0138213514410.7399/fh.2014.38.2.1081Set up of a protocol for heparin use in special patientsN. Manresa Ramón0Mª D. Nájera Pérez1Mª Ángeles Page del Pozo2I. Sánchez Martínez3Mª del M. Sánchez Catalicio4V. Roldán Schilling5Farmacia. Hospital Morales Meseguer. Murcia. EspañaFarmacia. Hospital Morales Meseguer. Murcia. España.Medicina Interna. Hospital Morales Meseguer. Murcia. EspañaFarmacia. Hospital Morales Meseguer. Murcia. EspañaFarmacia. Hospital Morales Meseguer. Murcia. EspañaOncohematología. Hospital Morales Meseguer. Murcia. EspañaLow-molecular weight (LMW) heparins bring a series of advantages as compared to non-fractionated heparin (NFH), such as safety, efficacy, bioavailability, fewer monitoring, and persistent anti-coagulant response. There exist, however, a concern about their use in particular patients that may require a special control, such as those with renal failure, age over 75 years, obesity, and pregnancy. The aim of this study was the set up between the department of Pharmacy, Hematology, and Internal Medicine of a consensus protocol for the follow-up ad monitoring of LMWH in patients requiring a special control. For this purpose, we carried out a bibliographical review of the different heparins used under de above mentioned conditions. Based on the evidence available and the consensus among the members of the working group, we established a protocol that contained recommendations on prophylaxis, management and monitoring by means of the determination of anti-Xa factor. Besides, we included some clues on the therapeutic figures of anti-Xa and administration schedules for obtaining anti-Xa values within the range. Enoxaparin was the selected heparin given the evidence and its availability at our center.http://www.aulamedica.es/fh/pdf/1081.pdfHeparinsLow molecular weight heparinsRenal failurePregnancy; ObesityElderlyEnoxaparinBemiparinDalteparinTinziparin; Fraxiparin |
| spellingShingle | N. Manresa Ramón Mª D. Nájera Pérez Mª Ángeles Page del Pozo I. Sánchez Martínez Mª del M. Sánchez Catalicio V. Roldán Schilling Set up of a protocol for heparin use in special patients Farmacia Hospitalaria Heparins Low molecular weight heparins Renal failure Pregnancy ; Obesity Elderly Enoxaparin Bemiparin Dalteparin Tinziparin ; Fraxiparin |
| title | Set up of a protocol for heparin use in special patients |
| title_full | Set up of a protocol for heparin use in special patients |
| title_fullStr | Set up of a protocol for heparin use in special patients |
| title_full_unstemmed | Set up of a protocol for heparin use in special patients |
| title_short | Set up of a protocol for heparin use in special patients |
| title_sort | set up of a protocol for heparin use in special patients |
| topic | Heparins Low molecular weight heparins Renal failure Pregnancy ; Obesity Elderly Enoxaparin Bemiparin Dalteparin Tinziparin ; Fraxiparin |
| url | http://www.aulamedica.es/fh/pdf/1081.pdf |
| work_keys_str_mv | AT nmanresaramon setupofaprotocolforheparinuseinspecialpatients AT madnajeraperez setupofaprotocolforheparinuseinspecialpatients AT maangelespagedelpozo setupofaprotocolforheparinuseinspecialpatients AT isanchezmartinez setupofaprotocolforheparinuseinspecialpatients AT madelmsanchezcatalicio setupofaprotocolforheparinuseinspecialpatients AT vroldanschilling setupofaprotocolforheparinuseinspecialpatients |